Pfizer Inc. (ETR:PFE)
20.62
+0.20 (0.98%)
Jun 6, 2025, 5:35 PM CET
Pfizer Employees
Pfizer had 81,000 employees as of December 31, 2024. The number of employees decreased by 7,000 or -7.95% compared to the previous year.
Employees
81,000
Change (1Y)
-7,000
Growth (1Y)
-7.95%
Revenue / Employee
€711,935
Profits / Employee
€89,847
Market Cap
114.79B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 81,000 | -7,000 | -7.95% |
Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
Dec 31, 2021 | 79,000 | 500 | 0.64% |
Dec 31, 2020 | 78,500 | -9,800 | -11.10% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 90,587 |
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Sartorius Aktiengesellschaft | 13,528 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 24,363 |
Pfizer News
- 8 hours ago - Pfizer, Arvinas submit marketing application for vepdegestrant to the FDA - Seeking Alpha
- 8 hours ago - Buy 7 Ideal 'Safer' May Dividends, Out Of 40 Reader Tags - Seeking Alpha
- 1 day ago - INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE) - Wallstreet:Online
- 1 day ago - Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis - The Motley Fool
- 1 day ago - Strong Cresemba (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea - Wallstreet:Online
- 2 days ago - These Stocks Are The High-Yield Dividend Investor's Best Friend - Seeking Alpha
- 2 days ago - INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE) - PRNewsWire
- 3 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC